Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

By G. Oxnard, K. Thress, R. Alden, R. Lawrance, C. Paweletz, M. Cantarini, J. Yang, J. Barrett, P. Jänne. Journal of Clinical Oncology, 2016

715 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018, background): “Finally, it should be noted that trials are currently underway to assess the value of these third-generation EGFR inhibitors as first-line treatment of EGFR-mutant lung adenocarcinoma.(220,221,236) Data are emerging(237) that a second acquired resistance mutation, C797S, can arise in tumors that hav”
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018, background): “One post hoc analysis of an osimertinib trial in NSCLC included 18 patients with EGFRT790Mdetected in plasma, but not in tumor tissue, and this small cohort of patients did less well than patients with T790M detected on tumor tissue genotyping.(30) To date, few trials have prospectively tested the o”